{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:20:38Z","timestamp":1761895238781},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,2,28]],"date-time":"2011-02-28T00:00:00Z","timestamp":1298851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,2,28]],"date-time":"2011-02-28T00:00:00Z","timestamp":1298851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1038\/bmt.2011.9","type":"journal-article","created":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T23:28:21Z","timestamp":1299022101000},"page":"18-23","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA"],"prefix":"10.1038","volume":"47","author":[{"given":"K W","family":"Douglas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A N","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P J","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Rahemtulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"D'Addio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R M","family":"Lemoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Maris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Uberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Noppeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S W","family":"Bokhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Worel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Mikala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Treisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,28]]},"reference":[{"key":"BFbmt20119_CR1","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. Medical Research Council Adult Leukemia Working Party. High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BFbmt20119_CR2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/sj.bmt.1704440","volume":"33","author":"C-K Lee","year":"2004","unstructured":"Lee C-K, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt20119_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","volume":"75","author":"LM Knudsen","year":"2005","unstructured":"Knudsen LM, Nielsen B, Gimsing P, Geisler C . Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27\u201333.","journal-title":"Eur J Haematol"},{"key":"BFbmt20119_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/sj.bmt.1702592","volume":"26","author":"R Yamamoto","year":"2000","unstructured":"Yamamoto R, Kanda Y, Matsuyama T, Oshima K, Nannya Y, Suguro M et al. Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure. Bone Marrow Transplant 2000; 26: 685\u2013688.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt20119_CR5","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/blood.V98.7.2059","volume":"98","author":"U Narayanasami","year":"2001","unstructured":"Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059\u20132064.","journal-title":"Blood"},{"key":"BFbmt20119_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","volume":"41","author":"G Calandra","year":"2008","unstructured":"Calandra G, McCarty J, McGuirk J, Tricot G, Crocker S-A, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and\/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331\u2013338.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt20119_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/bmt.2010.54","volume":"46","author":"RF Duarte","year":"2011","unstructured":"Duarte RF, Shaw BE, Mar\u00edn P, Kottaridis P, Ortiz M, Morante C et al. Plerixafor plus G-CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilisation attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46: 52\u201358.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt20119_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/scd.1.1998.7.241","volume":"7","author":"CH Weaver","year":"1998","unstructured":"Weaver CH, Tauer K, Zhen B, Schwartzberg LS, Hazelton B, Weaver Z et al. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. J Hematother 1998; 7: 241\u2013249.","journal-title":"J Hematother"},{"key":"BFbmt20119_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/sj.bmt.1705147","volume":"36","author":"R Goterris","year":"2005","unstructured":"Goterris R, Hernandez-Boluda JC, Teruel A, Gomez C, Lis MJ, Terol MJ et al. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. Bone Marrow Transplant 2005; 36: 847\u2013853.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt20119_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/sj.bmt.1704486","volume":"33","author":"S Boeve","year":"2004","unstructured":"Boeve S, Strupeck J, Creech S, Stiff PJ . Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997\u20131003.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt20119_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bbmt.2009.09.003","volume":"16","author":"R MacFarland","year":"2010","unstructured":"MacFarland R, Hard ML, Scarborough R, Badel K, Calandra G . A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. Biol Blood Marrow Transplant 2010; 16: 95\u2013101.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt20119_CR12","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1128\/AAC.44.6.1667-1673.2000","volume":"44","author":"CW Hendrix","year":"2000","unstructured":"Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E et al. Pharmacokinetics and safety of AMD1300, a novel antagonist of the CXCR4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667\u20131673.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFbmt20119_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/bmt.2010.128","volume":"46","author":"A D\u2019Addio","year":"2011","unstructured":"D\u2019Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients who are poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356\u2013363.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt20119_CR14","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","volume":"114","author":"S Kumar","year":"2009","unstructured":"Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimes. Blood 2009; 114: 1729\u20131735.","journal-title":"Blood"},{"key":"BFbmt20119_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01461.x","volume":"85","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M et al. Lenalidomide and dexamethasone for the treatment of refractory\/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 2010; 85: 1\u20135.","journal-title":"Eur J Haematol"},{"key":"BFbmt20119_CR16","unstructured":"Physicians\u2019 Desk Reference. Red Book 2009: Pharmacy's Fundamental Reference, 113th Edition. Physicians' Desk Reference, New Jersey, 2009."},{"key":"BFbmt20119_CR17","first-page":"749a","volume":"112","author":"E Delgado","year":"2008","unstructured":"Delgado E, LeMaistre CF, Bachier C, Smith B, L\u00f3pez-Gonz\u00e1lez G, Hougham M et al. Cost analysis of mobilization and autologous transplantation in patients who received AMD 3100 after failing standard mobilization. Blood (ASH Annual Meeting Abstracts) 2008; 112: 749a (Abstract 2151).","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt20119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt20119","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt20119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T15:08:10Z","timestamp":1648048090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt20119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,28]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["BFbmt20119"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2011.9","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,28]]},"assertion":[{"value":"6 August 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Professor Roberto M Lemoli has received research support and compensation as a member of the scientific advisory board of Genzyme, Italy. Dr Kenny Douglas and Professor Gordon Cook have received consultancy and speaker bureau payments from Genzyme. Professor Nina Worel has received speaker bureau payments from Genzyme.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}